Inhibiting tau production increased sensitivity of prostate cancer cells to the non-steroidal anti-androgen drug, bicalutamide and, in tissue, high tau expression was associated with poor overall survival in metastatic patients treated with androgen deprivation therapy (ADT) [69]. This evidence concerns the gene MAPT and prostate carcinoma.